Patents Assigned to ARCUTIS BIOTHERAPEUTICS, INC.
-
Publication number: 20240108609Abstract: Topical pharmaceutical compositions comprising roflumilast and solvents that are capable of dissolving high amounts of roflumilast. The pharmaceutical compositions are capable of dissolving high amounts of roflumilast relative to other commonly used solvents in approved topical pharmaceutical compositions. The solvents are particularly useful when combined with water to maintain high levels of dissolved roflumilast, which is highly insoluble in water.Type: ApplicationFiled: June 30, 2023Publication date: April 4, 2024Applicant: ARCUTIS BIOTHERAPEUTICS, INC.Inventors: David W. OSBORNE, Babak N. TOFIG, Frank WATANABE
-
Publication number: 20240024300Abstract: A method for altering the PK profile of a pharmaceutical formulation containing a PDE-4 inhibitor, such as roflumilast, to reduce the spike in Cmax. The spike in Cmax is reduced by topically administering the PDE-4 inhibitor in combination with one or more phosphate ester surfactants. Reducing the spike in Cmax will reduce gastrointestinal side effects and result in better patient compliance.Type: ApplicationFiled: July 17, 2023Publication date: January 25, 2024Applicant: ARCUTIS BIOTHERAPEUTICS, INC.Inventor: David W. Osborne
-
Publication number: 20240000760Abstract: An improved a method of treating a patient having a disorder responsive to PDE-4 inhibition by administering roflumilast. The improvement involves administering the roflumilast topically in a composition having a roflumilast release profile that produces in the patient a flattened plasma concentration time curve and a reduced Cmax relative to oral administration of a PDE4-inhibiting amount of roflumilast. Such disorders include inflammatory disorders such as inflammatory dermatoses, including psoriasis, atopic dermatitis and seborrheic dermatitis. Such disorders also include inflammatory diseases in a variety of organs, especially the lungs (asthma, COPD). Because of reduced side effects with topical administration due to the improved pharmacokinetics (PK) characteristics, it may be possible to provide higher systemic exposures (AUCs) with topical administration, resulting in greater therapeutic efficacy than with the oral route of administration.Type: ApplicationFiled: August 22, 2023Publication date: January 4, 2024Applicant: Arcutis Biotherapeutics, Inc.Inventor: David Osborne
-
Publication number: 20230414589Abstract: Roflumilast crystals have been shown to increase in size during storage. The size of the roflumilast crystals can affect the bioavailability and efficacy of a pharmaceutical composition. The growth of roflumilast crystals can be inhibited during storage by including hexylene glycol in the composition. The resulting composition has improved bioavailability and efficacy and can be used to inhibit phosphodiesterase 4 in a patient in need of such treatment.Type: ApplicationFiled: September 12, 2023Publication date: December 28, 2023Applicant: ARCUTIS Biotherapeutics Inc.Inventor: David W. OSBORNE
-
Publication number: 20230414511Abstract: Pharmaceutical compositions for the topical administration of a drug to the pilosebaceous unit and methods for administering the same. As disclosed herein, the inventors of the present invention have made the surprising discovery that pharmaceutical compositions comprising small particles of an active pharmaceutical ingredient and a silicone, such as dimethicone or cyclomethicone, can be administered to the pilosebaceous unit. The pharmaceutical composition can comprise SHR0302 or spironolactone as an active pharmaceutical ingredient.Type: ApplicationFiled: November 16, 2021Publication date: December 28, 2023Applicant: ARCUTIS BIOTHERAPEUTICS, INC.Inventors: David W. OSBORNE, Babak N. TOFIG
-
Patent number: 11819496Abstract: The present invention is directed to methods for improving the therapeutic outcome of treatment with roflumilast. The therapeutic outcome is improved by consistent delivery and/or a longer plasma half-life of a topically administered roflumilast composition. The roflumilast composition preferably includes dicetyl phosphate, ceteth-10 phosphate, diethylene glycol I monoethyl ether, and/or hexylene glycol.Type: GrantFiled: March 1, 2023Date of Patent: November 21, 2023Assignee: Arcutis Biotherapeutics, Inc.Inventor: David W. Osborne
-
Publication number: 20230364066Abstract: The present invention is directed to methods for improving the therapeutic outcome of treatment with roflumilast. The therapeutic outcome is improved by consistent delivery and/or a longer plasma half-life of a topically administered roflumilast composition. The roflumilast composition preferably includes dicetyl phosphate, ceteth-10 phosphate, diethylene glycol I monoethyl ether, and/or hexylene glycol.Type: ApplicationFiled: July 17, 2023Publication date: November 16, 2023Applicant: ARCUTIS BIOTHERAPEUTICS, Inc.Inventor: David W. OSBORNE
-
Publication number: 20230346689Abstract: Decreasing skin penetration lag times will improve the bioavailability of a topically administered roflumilast composition. A shorter skin penetration lag time provides quicker onset of disease relief and more consistent bioavailability as there is less transference to clothing or other people. The skin penetration lag time for roflumilast can be reduced by formulating a roflumilast composition to have a pH between 4.0-6.5 and/or combining roflumilast with an emulsifier blend comprising cetearyl alcohol, dicetyl phosphate and ceteth-10 phosphate.Type: ApplicationFiled: June 30, 2023Publication date: November 2, 2023Applicant: ARCUTIS Biotherapeutics Inc.Inventor: David W. OSBORNE
-
Publication number: 20230346690Abstract: Decreasing skin penetration lag times will improve the bioavailability of a topically administered roflumilast composition. A shorter skin penetration lag time provides quicker onset of disease relief and more consistent bioavailability as there is less transference to clothing or other people. The skin penetration lag time for roflumilast can be reduced by formulating a roflumilast composition to have a pH between 4.0-6.5 and/or combining roflumilast with an emulsifier blend comprising cetearyl alcohol, dicetyl phosphate and ceteth-10 phosphate.Type: ApplicationFiled: June 30, 2023Publication date: November 2, 2023Applicant: ARCUTIS Biotherapeutics Inc.Inventor: David W. OSBORNE
-
Publication number: 20230338383Abstract: The present invention is a method and composition comprising laureth-4 in topical formulations, wherein the laureth-4 increases the penetration of active ingredients across the skin. In a particularly preferred embodiment, the active ingredient is SHR0302.Type: ApplicationFiled: June 29, 2023Publication date: October 26, 2023Applicant: ARCUTIS BIOTHERAPEUTICS, INC.Inventor: David W. OSBORNE
-
Publication number: 20230338275Abstract: Decreasing skin penetration lag times will improve the bioavailability of a topically administered roflumilast composition. A shorter skin penetration lag time provides quicker onset of disease relief and more consistent bioavailability as there is less transference to clothing or other people. The skin penetration lag time for roflumilast can be reduced by formulating a roflumilast composition to have a pH between 4.0 - 6.5 and/or combining roflumilast with an emulsifier blend comprising cetearyl alcohol, dicetyl phosphate and ceteth-10 phosphate.Type: ApplicationFiled: June 30, 2023Publication date: October 26, 2023Applicant: ARCUTIS Biotherapeutics Inc.Inventor: David W. OSBORNE
-
Patent number: 11793796Abstract: Roflumilast crystals have been shown to increase in size during storage. The size of the roflumilast crystals can affect the bioavailability and efficacy of a pharmaceutical composition. The growth of roflumilast crystals can be inhibited during storage by including hexylene glycol in the composition. The resulting composition has improved bioavailability and efficacy and can be used to inhibit phosphodiesterase 4 in a patient in need of such treatment.Type: GrantFiled: November 23, 2020Date of Patent: October 24, 2023Assignee: Arcutis Biotherapeutics, Inc.Inventor: David W. Osborne
-
Publication number: 20230321057Abstract: The present invention is directed to a method of treating a fungal infection comprising administering topically, to a subject in need thereof, an anti-fungal effective amount of roflumilast. Preferably, topically administered roflumilast is used to treat fungal infections, fungal growth of and/or hypersensitivity to the fungi Malassezia spp. Patients may also be suffering from seborrheic dermatitis, dandruff, dupilumab facial redness, tinea versicolor, pityriasis versicolor, tinea circinata, tinea pedis, tinea unguium, tinea manus, tinea cruris, tinea corporis, tinea faciei, tinea capitis, and/or tinea incognito. Topically administered roflumilast is a quick and effective antifungal agent and presents a viable alternative to current antifungal treatments.Type: ApplicationFiled: June 15, 2023Publication date: October 12, 2023Applicant: ARCUTIS BIOTHERAPEUTICS, INC.Inventors: David Reuben BERK, Patrick Eugene BURNETT, Saori KATO, David W. OSBORNE
-
Publication number: 20230310397Abstract: The present invention is directed to methods for improving the therapeutic outcome of treatment with roflumilast. The therapeutic outcome is improved by consistent delivery and/or a longer plasma half-life of a topically administered roflumilast composition. The roflumilast composition preferably includes dicetyl phosphate, ceteth-10 phosphate, diethylene glycol I monoethyl ether, and/or hexylene glycol.Type: ApplicationFiled: March 1, 2023Publication date: October 5, 2023Applicant: ARCUTIS BIOTHERAPEUTICS, Inc.Inventors: David W. OSBORNE, Bhaskar CHAUDHURI, Archie W. THURSTON, JR.
-
Publication number: 20230310346Abstract: Topical pharmaceutical compositions comprising diethylene glycol monoethyl ether (DEGEE) maintained at an acidic pH. The pH of the formulation can be maintained at a pH of less than 6.3, or alternatively less than 6.0. Certain pharmaceutical composition further comprise an emulsifier blend of cetearyl alcohol, dicetyl phosphate, and ceteth-10 phosphate, which is manufactured by Croda under the tradename Crodafos™ CES.Type: ApplicationFiled: May 17, 2023Publication date: October 5, 2023Applicant: ARCUTIS BIOTHERAPEUTICS, INC.Inventors: David W. OSBORNE, Babak N. TOFIG
-
Publication number: 20230310345Abstract: Self-preserving topical pharmaceutical compositions comprising diethylene glycol monoethyl ether (DEGEE) maintained at an acidic pH. The pH of the formulation can be maintained at a pH of less than 6.3, or alternatively less than 6.0. The topical pharmaceutical compositions disclosed herein are self-preserving and can satisfy European Pharmacopeia Efficacy of Antimicrobial Preservation Criteria A without the addition of a traditional antimicrobial preservative. Certain pharmaceutical composition further comprise an emulsifier blend of cetearyl alcohol, dicetyl phosphate, and ceteth-10 phosphate, which is manufactured by Croda under the tradename Crodafos™ CES.Type: ApplicationFiled: August 15, 2022Publication date: October 5, 2023Applicant: ARCUTIS BIOTHERAPEUTICS, INC.Inventors: David W. OSBORNE, Babak N. TOFIG
-
Publication number: 20230285319Abstract: Self-preserving topical pharmaceutical compositions comprising diethylene glycol monoethyl ether (DEGEE) maintained at an acidic pH. The pH of the formulation can be maintained at a pH of less than 6.3, or alternatively less than 6.0. The topical pharmaceutical compositions disclosed herein are self-preserving and can satisfy European Pharmacopeia Efficacy of Antimicrobial Preservation Criteria A without the addition of a traditional antimicrobial preservative. Certain pharmaceutical composition further comprise an emulsifier blend of cetearyl alcohol, dicetyl phosphate, and ceteth-10 phosphate, which is manufactured by Croda under the tradename Crodafos™ CES.Type: ApplicationFiled: October 31, 2022Publication date: September 14, 2023Applicant: ARCUTIS BIOTHERAPEUTICS, INC.Inventors: David W. OSBORNE, Babak N. TOFIG
-
Patent number: 11730740Abstract: The present invention is a method and composition comprising laureth-4 in topical formulations, wherein the laureth-4 increases the penetration of active ingredients across the skin. In a particularly preferred embodiment, the active ingredient is SHR0302.Type: GrantFiled: July 27, 2021Date of Patent: August 22, 2023Assignee: ARCUTIS BIOTHERAPEUTICS, INC.Inventor: David W. Osborne
-
Patent number: 11707454Abstract: The present invention is directed to a method of treating a fungal infection comprising administering topically, to a subject in need thereof, an anti-fungal effective amount of roflumilast. Preferably, topically administered roflumilast is used to treat fungal infections, fungal growth of and/or hypersensitivity to the fungi Malassezia spp. Patients may also be suffering from seborrheic dermatitis, dandruff, dupilumab facial redness, Tinea versicolor, Pityriasis versicolor, Tinea circinata, Tinea pedis, Tinea unguium, Tinea manus, Tinea cruris, Tinea corporis, Tinea faciei, Tinea capitis, and/or Tinea incognito. Topically administered roflumilast is a quick and effective antifungal agent and presents a viable alternative to current antifungal treatments.Type: GrantFiled: December 3, 2021Date of Patent: July 25, 2023Assignee: Arcutis Biotherapeutics, Inc.Inventors: David Reuben Berk, Patrick Eugene Burnett, Saori Kato, David W. Osborne
-
Publication number: 20230226083Abstract: Pharmaceutical compositions for the topical administration of a drug to the pilosebaceous unit and methods for administering the same. As disclosed herein, the inventors of the present invention have made the surprising discovery that pharmaceutical compositions comprising small particles of an active pharmaceutical ingredient can be administered to the pilosebaceous unit. The pharmaceutical composition can comprise SHR0302 or spironolactone as an active pharmaceutical ingredient.Type: ApplicationFiled: March 22, 2023Publication date: July 20, 2023Applicant: ARCUTIS BIOTHERAPEUTICS, INC.Inventors: David W. OSBORNE, Babak N. TOFIG